Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18050382 | 0.81 | MAPT (0.41) | MAPT | |
| SCHEMBL29581038 | 0.79 | CA12 (0.44) | MAPT | |
| SCHEMBL29581876 | 0.79 | CA12 (0.44) | MAPT | |
| SCHEMBL4763802 | 0.79 | MAPT (0.39) | MAPT | |
| SCHEMBL24385090 | 0.77 | MAPT (0.38) | MAPT | |
| SCHEMBL21315069 | 0.76 | MAPT (0.41) | MAPT | |
| SCHEMBL12890963 | 0.76 | MAPT (0.41) | MAPT | |
| Chloromethane SCHEMBL28006060 | 0.76 | MAPT (0.53) | MAPT | |
| SCHEMBL17393057 | 0.75 | MAPT (0.36) | MAPT | |
| SCHEMBL17605 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11571426-B2 | Compositions for preventing or treating lupus | CHONG KUN DANG PHARMACEUTICAL CORP. | 2023-02-07 | — | — | US | disclosed |
| US-20210161905-A1 | Compositions for Preventing or Treating Dry Eye | CHONG KUN DANG PHARMACEUTICAL CORPORATION (KR) | 2021-06-03 | — | — | US | disclosed |
| US-20210077501-A1 | COMPOSITIONS FOR PREVENTING OR TREATING UVEITIS | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2021-03-18 | — | — | US | disclosed |
| US-20210040118-A1 | IMMUNOMODULATORS, COMPOSITIONS AND METHODS THEREOF | BETTA PHARMACEUTICALS CO., LTD (CN) | 2021-02-11 | — | — | US | disclosed |
| US-20200368245-A1 | COMPOSITIONS FOR PREVENTING OR TREATING LUPUS | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2020-11-26 | — | — | US | disclosed |
| US-9878986-B2 | Compounds for selective histone deacetylase inhibitors, and pharmaceutical composition comprising the same | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2018-01-30 | — | — | US | disclosed |
| US-9878986-B2 | Compounds for selective histone deacetylase inhibitors, and pharmaceutical composition comprising the same | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2018-01-30 | — | — | US | disclosed |
| US-20170152230-A9 | NOVEL COMPOUNDS FOR SELECTIVE HISTONE DEACETYLASE INHIBITORS, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2017-06-01 | — | — | US | disclosed |
| US-20170152230-A9 | NOVEL COMPOUNDS FOR SELECTIVE HISTONE DEACETYLASE INHIBITORS, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2017-06-01 | — | — | US | disclosed |
| US-20160083354-A1 | NOVEL COMPOUNDS FOR SELECTIVE HISTONE DEACETYLASE INHIBITORS, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARM CORP (KR) | 2016-03-24 | — | — | US | disclosed |
| US-7803956-B2 | Benzofuran derivatives useful for treating hyper-proliferative disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2010-09-28 | — | — | US | disclosed |
| US-7659412-B2 | Benzofuran derivatives useful for treating hyper-proliferative disorders | BAYER HEALTHCARE LLC (US) | 2010-02-09 | — | — | US | disclosed |
| US-7514468-B2 | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-04-07 | — | — | US | disclosed |
| US-20090023783-A1 | BENZOFURAN DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS | ZHANG CHENGZHI | 2009-01-22 | — | — | US | disclosed |
| US-7420066-B2 | Benzofuran derivatives useful for treating hyper-proliferative disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-09-02 | — | — | US | disclosed |
| US-20080132500-A1 | Antibiotic compounds | MERCK SHARP & DOHME CORP. | 2008-06-05 | — | — | US | disclosed |
| US-20080132500-A1 | Antibiotic compounds | MERCK SHARP & DOHME CORP. | 2008-06-05 | — | — | US | disclosed |
| US-20070111981-A1 | New (hetero)aryl compounds with MCH antagonistic activity and medicaments comprising these compounds | ROTH GERALD J | 2007-05-17 | — | — | US | disclosed |
| US-20070111981-A1 | New (hetero)aryl compounds with MCH antagonistic activity and medicaments comprising these compounds | ROTH GERALD J | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070111981-A1 | New (hetero)aryl compounds with MCH antagonistic activity and medicaments comprising these compounds | MCHR1, GPR119, MCHR2 | MAPT 4641/4885 |
| US-20210077501-A1 | COMPOSITIONS FOR PREVENTING OR TREATING UVEITIS | UACA, PDE6C, PDE6H | MAPT 402/4885 |
| US-11571426-B2 | Compositions for preventing or treating lupus | SSB, TLR9, TLR5 | MAPT 3853/4885 |
| US-20160083354-A1 | NOVEL COMPOUNDS FOR SELECTIVE HISTONE DEACETYLASE INHIBITORS, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | HDAC1, HDAC5, HDAC4 | MAPT 92/4885 |
| US-20170152230-A9 | NOVEL COMPOUNDS FOR SELECTIVE HISTONE DEACETYLASE INHIBITORS, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | HDAC1, HDAC5, HDAC4 | MAPT 92/4885 |
| US-20090023783-A1 | BENZOFURAN DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS | PCNA, MKI67, CDK4 | MAPT 4197/4885 |
| US-20200368245-A1 | COMPOSITIONS FOR PREVENTING OR TREATING LUPUS | SSB, TLR9, TLR5 | MAPT 3853/4885 |
| US-20210161905-A1 | Compositions for Preventing or Treating Dry Eye | PDE6H, PDE6C, PDE6D | MAPT 3128/4885 |
| US-20210040118-A1 | IMMUNOMODULATORS, COMPOSITIONS AND METHODS THEREOF | IL2, IL5, TSLP | MAPT 4396/4885 |
| US-20080132500-A1 | Antibiotic compounds | NRDC, MRPL21, PEPD | MAPT 2550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.